Ovarian Tumor Removal in India
Get Ovarian Tumor Removal at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Ovarian Tumor Removal in UAE
Ovarian Tumor Removal at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Ovarian tumor removal — encompassing laparoscopic cystectomy, oophorectomy, and cytoreductive surgery depending on tumor histology and stage — achieves complete surgical resection in 85–95% of appropriately selected cases, with five-year survival rates exceeding 90% for early-stage disease when performed at high-volume centers. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-accredited centers in Dubai and Abu Dhabi, offering world-class gynecologic oncology expertise at costs significantly below Western benchmarks. Patients benefit from seamless end-to-end coordination — from remote second opinions and visa facilitation to post-operative follow-up — ensuring clinical excellence and peace of mind throughout their medical journey.
Hospital Stay: 3–7 days (varies by surgical approach: 3–4 days for laparoscopic procedures; 5–7 days for open cytoreductive surgery) • Total Stay in Country (Fit-to-Fly): 2–4 weeks (laparoscopic/robotic cases typically cleared for international travel at 2 weeks; open or cytoreductive cases require 3–4 weeks to minimize deep-vein thrombosis and wound complication risk during long-haul flights) • Success Rate: 85–95% complete or optimal surgical resection rate; >90% five-year survival for Stage I disease; 70–75% for Stage III with optimal cytoreduction
What Is It?
Ovarian tumors represent a heterogeneous group of neoplasms arising from the surface epithelium, stromal cells, or germ cells of the ovary. Epithelial ovarian carcinoma — including serous, mucinous, endometrioid, and clear-cell subtypes — accounts for approximately 90% of malignant cases and remains the most lethal gynecologic malignancy globally, largely because over 70% of cases present at Stage III or IV when peritoneal dissemination has already occurred. Benign tumors — dermoid cysts (mature teratomas), serous and mucinous cystadenomas, and endometriomas — are far more common and carry an excellent prognosis following complete excision. Borderline tumors (low malignant potential) occupy an intermediate category requiring careful histopathologic classification to guide the extent of surgery and the need for adjuvant therapy.
The physiological impact of an ovarian tumor depends on its size, laterality, hormonal activity, and malignant potential. Large cysts exert mechanical compression on adjacent structures — the bladder, ureter, sigmoid colon, and inferior vena cava — producing urinary frequency, constipation, lower-extremity edema, and abdominal distension. Hormonally active tumors such as granulosa cell tumors secrete estrogen, causing abnormal uterine bleeding or precocious puberty, while Sertoli-Leydig cell tumors may cause virilization. Malignant tumors disrupt normal peritoneal homeostasis, generating ascites through increased vascular permeability mediated by VEGF overexpression, and can seed the omentum, diaphragmatic surfaces, and pelvic peritoneum widely.
The international standard of care for ovarian tumors is surgical — the extent determined by tumor biology, patient age, fertility intent, and disease stage. For benign or borderline lesions in women of reproductive age, fertility-sparing laparoscopic cystectomy or unilateral salpingo-oophorectomy (USO) is the preferred approach. For confirmed malignancy, comprehensive surgical staging — including total abdominal hysterectomy, bilateral salpingo-oophorectomy (BSO), omentectomy, pelvic and para-aortic lymph node dissection, and peritoneal biopsies — constitutes primary cytoreductive (debulking) surgery, ideally achieving R0 (no macroscopic residual disease). Advanced cases may receive neoadjuvant platinum-based chemotherapy (carboplatin/paclitaxel) prior to interval debulking surgery (IDS), a strategy validated by the CHORUS and EORTC 55971 trials.
Candidates
• **Confirmed ovarian mass on transvaginal ultrasound (TVUS)** with suspicious features: solid or mixed solid-cystic components, internal septations >3 mm, papillary projections, or absence of acoustic shadowing
• **Elevated serum tumor markers** warranting surgical evaluation: CA-125 (epithelial tumors), AFP and beta-hCG (germ cell tumors), inhibin A/B (granulosa cell tumors), CEA and CA 19-9 (mucinous tumors)
• **Risk stratification using IOTA (International Ovarian Tumor Analysis) simple rules or ADNEX model** classifying lesions as malignant-likely or indeterminate after imaging
• **Symptomatic benign cysts** ≥5 cm persistent beyond two menstrual cycles, or any cyst causing pain, torsion risk, or compressive symptoms regardless of size
• **Post-menopausal women** with any new-onset ovarian cyst >1 cm, given higher malignancy prevalence in this demographic
• **Women with BRCA1/BRCA2 pathogenic variants** or Lynch syndrome (MLH1, MSH2, MSH6, PMS2) who have completed childbearing and opt for risk-reducing bilateral salpingo-oophorectomy (RRSO)
• **Required pre-operative diagnostics:** Contrast-enhanced CT of abdomen and pelvis (CT-CAP), MRI pelvis with DWI sequences for characterization, PET-CT scan for staging in confirmed malignancy, full blood count, renal and liver function tests, coagulation profile, serum electrolytes, ECG, and echocardiogram (ECHO) if cardiopulmonary reserve is relevant to open surgery
• **Genetic counseling and germline BRCA testing** prior to surgery for all high-grade serous carcinomas (HGSC) to inform surgical extent and PARP inhibitor eligibility post-operatively
• **Contraindications and relative contraindications:** Uncontrolled cardiopulmonary disease precluding general anesthesia (ASA Class IV–V), uncorrectable coagulopathy, active systemic infection, bowel obstruction without prior optimization, pregnancy (requires individualized timing), and extreme obesity (BMI >50) may require staged or modified surgical planning
Procedure
**1. Laparoscopic Ovarian Cystectomy (Fertility-Sparing)** The gold-standard approach for benign cysts in reproductive-age women. Using 3–4 port entry and a 10 mm zero-degree or 30-degree HD laparoscope, the surgeon dissects the cyst wall from the ovarian cortex using hydrodissection and cold scissors, preserving primordial follicle density. An endobag (e.g., LapSac) is mandatory for specimen retrieval to prevent intraperitoneal spillage of dermoid contents (chemical peritonitis) or borderline/malignant cells. Bipolar diathermy achieves hemostasis with minimal thermal cortical damage. Ovarian reconstruction with 3-0 Vicryl sutures restores normal anatomy.
**2. Robotic-Assisted Laparoscopic Surgery (da Vinci Xi/SP Platform)** Increasingly used in India and the UAE at tertiary centers for complex adnexal masses, endometriosis-associated cysts, and select early-stage malignancies. The 3D high-definition magnification (10×), EndoWrist articulation (7 degrees of freedom), and tremor filtration provide ergonomic superiority over conventional laparoscopy in deep pelvis dissection, ureter identification, and suturing. Robotic platforms available at partner hospitals include the da Vinci Xi (four-arm system) and the single-port da Vinci SP, the latter offering improved cosmesis. Studies demonstrate equivalent oncologic outcomes to open surgery for Stage I–II disease with faster recovery.
**3. Unilateral Salpingo-Oophorectomy (USO) / Bilateral Salpingo-Oophorectomy (BSO)** Performed laparoscopically or robotically for unilateral malignant or high-risk masses. The infundibulopelvic (IP) ligament containing the ovarian vessels is secured with an energy device (LigaSure, Harmonic scalpel) or suture ligation. Frozen section intraoperative histopathology guides real-time decision-making: if malignancy is confirmed, the procedure is immediately converted to comprehensive staging. BSO is standard for bilateral disease, postmenopausal patients, and BRCA carriers undergoing RRSO.
**4. Comprehensive Surgical Staging (Open / Laparoscopic)** For confirmed epithelial ovarian cancer (Stages I–II), staging includes: total hysterectomy + BSO + infracolic omentectomy + pelvic and para-aortic lymphadenectomy (to the level of the renal vessels) + peritoneal washings + random peritoneal biopsies (right and left paracolic gutters, cul-de-sac, right diaphragm). The GOG and ESGO guidelines mandate systematic lymphadenectomy as it upstages up to 30% of apparently early-stage cases, altering adjuvant chemotherapy decisions.
**5. Primary Cytoreductive (Debulking) Surgery for Advanced Disease (Stage III–IV)** The surgical objective is achieving R0 resection — no visible residual tumor. This may require: omentectomy, pelvic and abdominal peritonectomy (HIPEC-associated centers can perform diaphragmatic stripping), bowel resection with anastomosis, splenectomy, liver surface resection, and urologic procedures. Residual disease <1 cm (optimal cytoreduction) vs. R0 (complete cytoreduction) significantly impacts PFS and OS. The AGO DESKTOP III trial confirmed survival benefit of secondary cytoreduction in platinum-sensitive recurrence with a positive AGO score (ECOG PS 0, ascites-free, R0 at primary surgery).
**6. Interval Debulking Surgery (IDS) after Neoadjuvant Chemotherapy (NACT)** For patients presenting with unresectable Stage IIIC–IV disease (massive ascites, extensive pleural effusion, poor PS), 3–4 cycles of carboplatin (AUC 5–6) + paclitaxel (175 mg/m²) or carboplatin + docetaxel are administered first. Response is assessed by CT-CAP and CA-125 kinetics (KELIM score). IDS aims for R0 and is followed by 3 additional chemotherapy cycles. PARP inhibitor maintenance (olaparib, niraparib, or rucaparib) post-chemotherapy is now standard for BRCA-mutant and HRD-positive tumors per SOLO-1, PRIMA, and PAOLA-1 trial data.
**7. HIPEC (Hyperthermic Intraperitoneal Chemotherapy)** At select high-volume centers in India and the UAE, HIPEC with cisplatin (42°C for 90 minutes) is offered immediately following cytoreductive surgery for peritoneal carcinomatosis. The van Driel NEJM 2018 trial demonstrated a 3.5-month OS improvement in Stage III patients receiving HIPEC versus surgery alone. Patient selection is critical: Peritoneal Cancer Index (PCI) ≤20 and CC-0/CC-1 cytoreduction are prerequisites.
Cost of Ovarian Tumor Removal: India vs. UAE
The cost of ovarian tumor removal varies significantly based on the surgical approach (laparoscopic cystectomy vs. open cytoreductive surgery with HIPEC), tumor complexity, hospital tier, and destination country. India offers world-class gynecologic oncology at 40–60% lower cost than the UAE due to lower operational overhead while maintaining equivalent JCI and NABH accreditation standards. The UAE, particularly Dubai and Abu Dhabi, provides a premium hospital environment with luxury amenities, shorter flight times for patients from Europe, the Middle East, and Africa, and seamless Arabic-language support. Both destinations offer internationally trained gynecologic oncologists, robotic surgical platforms, and real-time intraoperative frozen section capabilities.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $3,000 – $12,000 | ~53% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $7,000 – $25,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
**Phase 1 — Remote Pre-Consultation (Weeks 1–2 before travel)**
Patient submits medical records (ultrasound, MRI, CT, CA-125, biopsy if available) via GAF Healthcare's secure portal. A board-certified gynecologic oncologist at the partner hospital issues a detailed second opinion and surgical plan within 48–72 hours. Genetic counseling for BRCA/Lynch testing is initiated remotely if indicated. Cost estimate, tentative surgery date, and visa documentation checklist are provided.
**Phase 2 — Pre-Arrival Logistics (Week 2)**
GAF Healthcare facilitates the Indian e-Medical Visa (typically approved in 3–5 business days) or UAE tourist/medical entry. Airport pickup by a dedicated medical concierge, hotel or hospital guest house booking for the accompanying attendant, and SIM card/connectivity assistance are arranged.
**Phase 3 — In-Hospital Pre-Operative Work-Up (Days 1–2 in destination)**
Patient is admitted or seen in OPD for: repeat TVUS and pelvic MRI (if imaging is >6 weeks old), full pre-operative blood panel, anesthesia assessment (ASA classification, airway grading), cardiology clearance (ECG ± ECHO) if open surgery is planned, bowel preparation for cytoreductive cases, and multidisciplinary tumor board (MDT) review confirming surgical strategy. Informed consent is obtained with the assistance of a certified medical interpreter.
**Phase 4 — Surgical Day**
Procedure performed under general anesthesia (endotracheal intubation with muscle relaxation). Laparoscopic/robotic cases: 90–180 minutes operative time. Open cytoreductive surgery: 3–6 hours. Intraoperative frozen section sent for histopathology within 20 minutes to guide real-time surgical decision-making. Blood loss monitoring with cell salvage available for open cases. Patient recovers in a dedicated HDU/ICU for 2–4 hours post-operatively before transfer to the gynecology ward.
**Phase 5 — In-Hospital Recovery (Days 1–5 post-op)**
• Day 1: IV analgesia (multimodal: paracetamol + ketorolac + low-dose opioid PCA), urinary catheter, compression stockings + LMWH (enoxaparin) for DVT prophylaxis, early ambulation encouraged at 12–24 hours for laparoscopic cases.
• Day 2–3: Catheter removal (laparoscopic) or Day 3–4 (open), liquid diet progressing to soft diet, wound inspection, drain removal assessment.
• Day 4–5: Discharge planning for laparoscopic cases. Open cases may require Days 5–7 for adequate bowel function return, wound stability, and pain control on oral medications.
**Phase 6 — Post-Discharge Recovery (Weeks 1–4 in destination)**
• Laparoscopic/robotic cystectomy or USO: Light activity in Days 5–10, abdominal binder recommended, no driving. Suture/staple removal at Day 7–10. Cleared for air travel (short-haul <4 hours) at Day 14, long-haul at Day 21 with compression stockings and in-flight ambulation.
• Open staging or cytoreductive surgery: No heavy lifting for 6 weeks, wound review at Days 7 and 14, abdominal binder 4–6 weeks, fit-to-fly assessment at Week 3–4. If HIPEC was performed, additional monitoring for renal function and bone marrow suppression (nadir at Day 10–14).
• Pathology report (final histopathology, ER/PR/HER2, BRCA somatic testing) issued within 5–7 days post-surgery and discussed in a follow-up MDT meeting. Adjuvant chemotherapy planning initiated before patient's return home if indicated.
**Phase 7 — Return Home & Remote Follow-Up**
GAF Healthcare provides the patient with a comprehensive medical discharge summary, operative notes, pathology report, and imaging CDs for continuity of care with the home oncologist. Teleconsultation follow-ups at 2 weeks, 6 weeks, and 3 months post-surgery are included in the care package.
Risks & Considerations
Ovarian tumor removal, like all major gynecologic surgery, carries procedure-specific and anesthesia-related risks that patients must understand before consenting. Intraoperative risks include inadvertent cyst rupture during laparoscopic cystectomy — particularly for large mucinous or dermoid cysts — which can cause chemical peritonitis (dermoid spillage) or theoretical upstaging if malignant cells are disseminated; this is mitigated by mandatory endobag use. Injury to adjacent structures — ureter, bladder, sigmoid colon, and major pelvic vessels — occurs in 1–3% of cases, with risk elevated in endometriosis-related distorted anatomy or bulky nodal dissections. Intraoperative hemorrhage requiring transfusion is reported in 2–8% of cytoreductive surgeries. Post-operative complications include wound infection (2–5%), ileus or bowel obstruction (3–7% after open cytoreduction), anastomotic leak if bowel resection was performed (~3–5%), deep vein thrombosis and pulmonary embolism (3–10% without adequate LMWH prophylaxis — prolonged LMWH for 28 days post-discharge is recommended by ESGO guidelines for malignant cases), and lymphocyst formation after lymphadenectomy. Premature surgical menopause following BSO in premenopausal women produces vasomotor symptoms, genitourinary atrophy, reduced bone mineral density, and increased cardiovascular risk; hormone replacement therapy (HRT) is generally safe and recommended until age 50 in non-hormone-sensitive tumor histologies. HIPEC-specific risks include nephrotoxicity from intraperitoneal cisplatin (mitigated by aggressive IV hydration and amifostine), myelosuppression (nadir Day 10–14), and prolonged ileus. Overall 30-day mortality for elective laparoscopic ovarian surgery at high-volume centers is <0.1%; for open cytoreductive surgery it ranges from 0.5–2% depending on extent of disease and patient comorbidity burden.
Top Hospitals for Ovarian Tumor Removal
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Aster Hospital Dubai
Dubai, UAE
Top Doctors for Ovarian Tumor Removal
Internationally trained specialists in Gynecology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Tarang Preet Kaur
MBBS, MS, MRCOG, MCh, Fellowship in Urogynaecology, Fellowship in Cosmetic Gynaecology
Urogynaecologist
Max Super Speciality Hospital, Saket, New Delhi, India
11+ Yearsof experience
Dr. Tarang Preet Kaur is a Consultant in Urogynaecology with over 11 years of clinical experience, currently practicing at Max Super Speciality Hospital, Saket in New Delhi. She holds an MCh in Urogynaecology from Edge Hill University, United Kingdom (2024), the MRCOG from the Royal College of Obstetricians & Gynaecologists, and an MS in Obstetrics & Gynaecology from Maulana Azad Medical College, Delhi. Her dual qualification across India and the UK… Read more
Dr. Amrinder Kaur Bajaj
MBBS, MD — Obstetrics & Gynaecology (Gold Medalist), Senior Residency — Obstetrics & Gynaecology, FRSH — Fellow of the Royal Society of Health, FIAMS — Fellow of the Indian Association of Medical Specialists
Obstetrician & Gynaecologist
Fortis Hospital, Gurgaon, Gurgaon, India
42+ Yearsof experience
Dr. Amrinder Kaur Bajaj is one of Delhi-NCR's most experienced gynaecologists, with over four decades spent caring for women at every stage of life. She currently practises as a Consultant in Obstetrics & Gynaecology at Fortis Hospital, Gurgaon, where she brings together deep clinical knowledge and a quietly reassuring bedside manner that patients — and their families — find genuinely comforting. Her academic journey set a high bar early on. She completed… Read more
Dr. Anuradha Khurana
MBBS, DGO (Diploma in Obstetrics & Gynaecology), PG in High Risk Pregnancy and Infertility
Gynecologist & Obstetrics Specialist
Artemis Hospital, New Delhi, India
20+ Yearsof experience
Dr. Anuradha Khurana is a Senior Consultant in Obstetrics and Gynecology at Artemis Hospital, Delhi, with over two decades of hands-on experience in women's health. She is particularly well regarded for her work in high-risk pregnancy management, uterine conditions like fibroids and endometriosis, and complex gynecological surgeries. Patients and families consistently describe her as someone who takes the time to truly listen — and to explain things in a… Read more
Dr. Aswari Kesari Kapoor
MBBS, DGO (Diploma in Gynaecology & Obstetrics), CPS (College of Physicians and Surgeons), DNB (Diplomate of National Board) — Obstetrics & Gynaecology
Obstetrician & Gynecologist
Indraprastha Apollo Hospital, New Delhi, India
23+ Yearsof experience
Dr. Aswari Kesari Kapoor is a seasoned Obstetrician and Gynecologist with over 23 years of hands-on clinical experience. She practices at Indraprastha Apollo Hospital in New Delhi — one of India's most respected multi-specialty institutions. Over the course of her career, she has built a strong reputation for managing complex gynecological conditions alongside high-risk pregnancies, all with a calm and reassuring bedside manner that patients consistently… Read more
Dr. Bindhu K S
MBBS, DNB (Obstetrics & Gynecology), Fellowship in Minimal Access Surgery, FICOG (Fellowship of the Indian College of Obstetricians and Gynaecologists), Certificate in Gynecologic and Obstetric Sonography, Certificate in Appreciation of Well Being in Fetal Heart Disease
Obstetrician & Gynecologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
23+ Yearsof experience
Dr. Bindhu K S is a seasoned Obstetrician and Gynecologist based in Mumbai, currently practicing at Apollo Hospitals, Navi Mumbai. With over two decades of clinical experience, she brings together expertise in both obstetrics and advanced minimally invasive gynecologic surgery. Whether a patient comes with a complex fibroid, troublesome endometriosis, or a high-risk pregnancy, Dr. Bindhu approaches each situation with careful thought and genuine care. Her… Read more
Frequently Asked Questions — Ovarian Tumor Removal
The cost of ovarian tumor removal varies by procedure type and destination. In India, at JCI- and NABH-accredited hospitals, laparoscopic ovarian cystectomy or unilateral salpingo-oophorectomy typically costs USD 3,000–6,000, while comprehensive open cytoreductive surgery for malignant disease (including staging lymphadenectomy and omentectomy) ranges from USD 7,000–12,000. HIPEC (Hyperthermic Intraperitoneal Chemotherapy) combined with cytoreduction may reach the upper end of this range. In the UAE (Dubai and Abu Dhabi), at JCI- and DHA-accredited centers, the same laparoscopic procedures range from USD 7,000–12,000, and open cytoreductive surgery costs USD 15,000–25,000 depending on hospital tier and operative complexity. India is typically 40–60% less expensive than the UAE for equivalent clinical outcomes, making it the preferred destination for cost-sensitive international patients. Both destinations include surgery, anesthesia, hospital stay, standard medications, nursing care, and one post-operative review in their packages. GAF Healthcare provides a fully itemized cost estimate before any commitment is required.
The minimum safe stay before an international flight depends on the type of surgery performed and is guided by the risk of venous thromboembolism (VTE) and wound complications during prolonged air travel. For laparoscopic ovarian cystectomy or unilateral salpingo-oophorectomy in benign disease, most patients are cleared for short-haul flights (<4 hours) at Day 10–14 post-surgery and long-haul international flights at Day 14–21, provided they are ambulating normally, have no wound complications, and are off opioid analgesics. For open comprehensive staging surgery or cytoreductive surgery for malignancy, the fit-to-fly threshold is typically 3–4 weeks post-operatively. ESGO and ACOG guidelines recommend extended LMWH (low molecular weight heparin) prophylaxis for 28 days after ovarian cancer surgery, compression stockings during the flight, and in-flight ambulation every 1–2 hours to minimize DVT risk. If HIPEC was performed, renal function and blood counts must be rechecked before departure. GAF Healthcare's coordinating physician issues a formal fit-to-fly clearance letter for the airline and travel insurer before the patient departs.
Success rates for ovarian tumor removal depend heavily on tumor type, stage, and whether complete (R0) surgical resection is achieved. For benign ovarian cysts (dermoid cysts, serous/mucinous cystadenomas, endometriomas), laparoscopic cystectomy or oophorectomy is curative in over 95% of cases, with recurrence rates of 10–30% for cystectomy versus <5% for oophorectomy in benign disease. For borderline ovarian tumors (low malignant potential), fertility-sparing surgery achieves 5-year survival rates exceeding 95% for Stage I disease. For malignant epithelial ovarian cancer, outcomes are strongly stage-dependent: Stage I — 5-year survival >90%; Stage II — 70–80%; Stage III with optimal (R0) cytoreduction — 40–50% 5-year survival; Stage IV — 20–30%. The single most important prognostic surgical factor is achieving R0 resection (no macroscopic residual disease), which is why GAF Healthcare partners exclusively with high-volume gynecologic oncology centers where surgeons perform >50 cytoreductive procedures annually. PARP inhibitor maintenance therapy (olaparib, niraparib) in BRCA-mutant or HRD-positive patients has further improved progression-free survival by 36–50% in recent Phase III trials (SOLO-1, PRIMA), and these therapies are available at all partner hospitals in both India and the UAE.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a complete, medically integrated concierge service that eliminates the logistical burden of international medical travel, allowing patients and their families to focus entirely on recovery.
**India — Visa & Entry:** Most nationalities are eligible for India's e-Medical Visa, which is processed online within 3–5 business days and allows a 60-day stay extendable up to 180 days. GAF Healthcare prepares the complete application package — including the hospital's official invitation letter, confirmed appointment letter, and supporting medical records — and submits it on the patient's behalf. Two accompanying attendants are also eligible for the e-Medical Attendant Visa under the same application cycle.
**UAE (Dubai / Abu Dhabi) — Visa & Entry:** Citizens of over 120 countries receive a visa-free or visa-on-arrival entry to the UAE for 30–90 days, covering the typical treatment and recovery period. For nationalities requiring a prior visa, GAF Healthcare coordinates with the hospital's international patient services office to issue a formal medical invitation letter, which significantly expedites consular processing. UAE Golden Visa options exist for patients undertaking long-term treatment programs.
**Airport & Ground Transfers:** Dedicated air-conditioned vehicle pickup at arrival airport — with a GAF Healthcare patient coordinator holding a name placard — is standard for all packages. Wheelchair-accessible vehicles and stretcher-equipped medical transport are available on request for mobility-impaired patients.
**Certified Medical Interpreters:** GAF Healthcare provides certified interpreters in Arabic, Russian, French, Swahili, Bangla, and other major languages throughout all clinical consultations, surgical consenting sessions, and discharge briefings in both India and the UAE, ensuring zero language barrier in shared decision-making.
**Accommodation for Attendants:** Partner hospitals in India offer on-campus or adjacent guest houses (from USD 25–60/night). In the UAE, GAF Healthcare has negotiated corporate rates at 3- and 4-star hotels within 5–10 minutes of the treating hospital (from USD 80–150/night). For lengthy stays, furnished serviced apartments with kitchen access are arranged for cost efficiency.
**In-Country Care Coordination:** A dedicated GAF Healthcare case manager is available 24/7 via WhatsApp and phone throughout the patient's stay. They coordinate all inter-departmental appointments (radiology, pathology, oncology MDT, physiotherapy), pharmacy procurement, SIM card and local currency assistance, and dietary accommodation. They also liaise with the patient's home oncologist for real-time case updates and facilitate remote follow-up teleconsultations after the patient returns home.